title: Double-blind placebo-controlled trial of quetiapine in anorexia nervosa.
abstract: OBJECTIVE
  Our objective is to determine whether quetiapine was superior to placebo in increasing weight or reducing core symptoms of anorexia nervosa as assessed by the Yale-Brown-Cornell Eating Disorder Scale and the Eating Disorder Inventory-2.
  
  
  METHODS
  Participants were randomised to 8 weeks of quetiapine or placebo.
  
  
  RESULTS
  There are 21 participants who signed informed consent, 15 were randomised, 14 returned for at least one visit after receiving drug and 10 completed the study. There were no differences between drug and placebo in questionnaire scores, weight or measures of anxiety or depression.
  
  
  CONCLUSIONS
  There was no difference between quetiapine and placebo on weight gain or core symptoms. Small effect sizes suggest that a higher number of participants would not increase significant differences between groups.
authors.affiliation: Department of Pediatrics, Health Sciences Center, University of South Florida, Tampa, FL, USA.
authors.forename: Pauline S
authors.initials: PS
authors.lastname: Powers
authors.forename: Megan
authors.initials: M
authors.lastname: Klabunde
authors.forename: Walter
authors.initials: W
authors.lastname: Kaye
mesh_terms: D000328:Adult; D000856:Anorexia Nervosa / Q000188:drug therapy* / Q000523:psychology; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D003987:Dibenzothiazepines / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D011569:Psychiatric Status Rating Scales; D000069348:Quetiapine Fumarate; D011795:Surveys and Questionnaires
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate